Eli Lilly and CoHAM:LLY +3.96%98 OCF Yield % is 1.90 as of Jun. 27, 2026, which is 44% below its 10-year median of 3.37. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,212.75 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 58.71% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Eli Lilly and Co OCF Yield % Related Terms
Eli Lilly and Co OCF Yield % Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (HAM:LLY) has a OCF Yield % of 1.90 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eli Lilly and Co and its competitors. This is 44% below median its historical median of 3.37. Over the past decade, Eli Lilly and Co's OCF Yield % has ranged from 0.45 to 7.20. According to the industry distribution chart, Eli Lilly and Co ranks #590 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is Eli Lilly and Co's OCF Yield % too high?
Eli Lilly and Co's current OCF Yield % of 1.90 is 44% below median its 10-year median of 3.37. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 7.20. The Drug Manufacturers industry median OCF Yield % is 3.61. Eli Lilly and Co's value of 1.90 is 47.4% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #590 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's OCF Yield % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #590 out of 1005 companies for OCF Yield %. This places Eli Lilly and Co in the lower half of its industry. The industry median OCF Yield % is 3.61. Eli Lilly and Co's value of 1.90 is 47.4% below this benchmark. Historically, Eli Lilly and Co's own OCF Yield % has ranged from 0.45 to 7.20 over the past decade. While the company's 10-year median is 3.37 vs. the industry median of 3.61, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current OCF Yield % of 1.90 is 47.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current OCF Yield % is 1.90, which is 44% below median its own 10-year median of 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,212.75, compared to a current price of €1,039.40 — trading 14.3% below its estimated fair value. The current OCF Yield % is 1.90, which is 44% below median its 10-year median of 3.37 and 47.4% below the Drug Manufacturers industry median of 3.61. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current OCF Yield % is 1.90 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of €1,039.40 is trading 14.3% below its estimated GF Value™ of €1,212.75.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for HAM:LLY:
OCF Yield %: 1.90 (44% below median its 10-year median of 3.37)
GF Value™: €1,212.75 vs. price of €1,039.40 (14.3% below fair value)
Industry Position: 47.4% below the Drug Manufacturers median (#590 of 1005)
No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for HAM:LLY
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:LLY has been successfully added to your 
